bioAffinity Technologies, Inc. (BIAFW) community

BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value

$0.24+0.00 (0.00%)

Close on Oct 30, 2026Market cap $23.58MP/E –Yield –

Community

Notes and questions about bioAffinity Technologies from other investors

No posts about BIAFW yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in bioAffinity Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Aug 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BIAFW.

Compare: BIAFW vs AIDX · BIAFW vs ABSI · BIAFW vs MXCT · BIAFW vs FOXO · BIAFW vs OABI

Revenue growth-23.2% · median 15.4%

Operating margin-209.8% · median -125.2%

Net margin-257.3% · median -111.4%

Company	Revenue	Growth
OABI	$40.21M	+90.6%
MXCT	$31.05M	-13.2%
FOXO	$17.86M	+44.0%
BIAFW	$5.90M	-23.2%
ABSI	$1.56M	-62.3%
AIDX	–	–

Company

Next earnings (est.): Nov 13, 2026, before open
Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 57
Auditor: WithumSmith+Brown, PC
SEC CIK: 1712762

Advertisement
300 × 250